Table 1. Baseline Characteristics of Men With AAMI in the Cognitive Function Trial and of All Men Enrolled in the Testosterone Trialsa.
| Men With AAMI in the Cognitive Function Trial | All Men Enrolled in the Testosterone Trials | |||
|---|---|---|---|---|
| Placebo (n = 246) | Testosterone (n = 247) | Placebo (n = 394) | Testosterone (n = 394) | |
| Demographics, No. (%) | ||||
| Age, mean (SD), y | 72.8 (6.1) | 72.3 (5.8) | 72.3 (5.8) | 72.1 (5.7) |
| Race | ||||
| White | 217 (88.2) | 213 (86.2) | 350 (88.8) | 348 (88.3) |
| African American | 13 (5.3) | 14 (5.7) | 20 (5.1) | 21 (5.3) |
| Other | 16 (6.5) | 20 (8.1) | 24 (6.1) | 25 (6.3) |
| Ethnicitya | ||||
| Hispanic | 7 (2.8) | 15 (6.1) | 10 (2.5) | 18 (4.6) |
| Non-Hispanic | 239 (97.2) | 232 (93.9) | 384 (97.5) | 375 (95.2) |
| College graduate | 112 (45.5) | 130 (52.6) | 197 (50.0) | 213 (54.1) |
| Married or living with partner | 189 (76.8) | 180 (72.9) | 303 (76.9) | 289 (73.4) |
| Concomitant Conditions, No. (%) | ||||
| BMI, mean (SD) | 30.7 (3.6) | 31.1 (3.5) | 31.0 (3.5) | 31.0 (3.5) |
| BMI >30 | 145 (58.9) | 164 (66.4) | 245 (62.2) | 251 (63.7) |
| Alcohol use (No. of drinks/wk), median (IQR) | 1.0 (0-6) | 1.0 (0-4) | 1.0 (0-5) | 1.0 (0-5) |
| Smoking | ||||
| Current | 24 (9.8) | 15 (6.1) | 34 (8.6) | 30 (7.6) |
| Ever | 165 (67.1) | 163 (66.0) | 268 (68.0) | 256 (65.0) |
| Diabetes | 88 (35.8) | 91 (36.8) | 144 (36.5) | 148 (37.6) |
| Hypertension | 172 (69.9) | 179 (72.5) | 279 (70.8) | 286 (72.6) |
| History of myocardial infarction | 44 (17.9) | 35 (14.2) | 63 (16.0) | 53 (13.5) |
| History of stroke | 12 (4.9) | 12 (4.9) | 17 (4.3) | 16 (4.1) |
| Sleep apnea | 40 (16.3) | 58 (23.5) | 76 (19.3) | 77 (19.5) |
| Hyperlipidemias | 186 (75.6) | 193 (78.1) | 295 (74.9) | 302 (76.6) |
| Coronary artery disease | 73 (29.7) | 67 (27.1) | 112 (28.4) | 101 (25.6) |
| Other Characteristics, No. (%) | ||||
| Medication use | ||||
| α-Blocking agents | 33 (13.4) | 38 (15.4) | 46 (11.7) | 55 (14.0) |
| 5α-Reductase inhibitors | 11 (4.5) | 9 (3.6) | 16 (4.1) | 14 (3.6) |
| Phosphodiesterase inhibitors | 20 (8.1) | 20 (8.1) | 36 (9.1) | 30 (7.6) |
| Antihypertensives | 169 (68.7) | 168 (68.0) | 270 (68.5) | 272 (69.0) |
| Antidepressants | 36 (14.6) | 36 (14.6) | 54 (13.7) | 54 (13.7) |
| Sex hormones, mean (SD) | ||||
| Testosterone, ng/dL | 234.0 (67.4) | 234.4 (65.1) | 236.1 (66.7) | 231.8 (63.1) |
| Free testosterone, pg/mL | 64.5 (23.1) | 63.0 (22.4) | 64.9 (23.4) | 62.0 (21.4) |
| Dihydrotestosterone, ng/dL | 21.0 (12.3) | 21.2 (10.5) | 20.8 (13.0) | 21.2 (11.6) |
| Estradiol, pg/mL | 20.3 (6.4) | 20.3 (6.4) | 20.4 (6.3) | 20.3 (6.7) |
| Sex hormone–binding globulin, nM | 29.5 (13.6) | 30.9 (14.5) | 29.5 (14.7) | 31.3 (15.2) |
Abbreviations: AAMI, age-associated memory impairment; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); IQR, interquartile range.
SI conversion factors: To convert dihydrotestosterone to nmol/L, multiply by 0.0344; estradiol to pmol/L, multiply by 3.671; free testosterone to pmol/L, multiply by 3.47; testosterone to nmol/L, multiply by 0.0347.
a
Ethnicity data were missing for 1 participant in the testosterone group for all men in the Testosterone Trials.